Fever is a state of elevated body temperature
and a common symptom associated with systemic infectious diseases and inflammation.
The most commonly used experimental model of fever comprises systemic administration
of lipopolysaccharide (LPS), a component of the outer membrane of Gram-negative
bacteria. The injection of LPS induces the expression of cyclooxygenase-2 (COX-2)
and microsomal prostaglandin E synthase-1 (mPGES-1) in peripheral and central
cells including macrophages of the lung and liver, and endothelial cells of
the hypothalamus. The COX-2 and mPGES-1 induction results in conversion of arachidonic
acid to PGE
2 (1-3). PGE
2,
in turn, induces fever by stimulating E type prostaglandin (EP) receptor subtype
EP
3 (and possibly EP
1)
in the thermoregulatory center of the hypothalamus (4, 5), thereby being the
most important proximal mediator of the febrile response (6).
In contrast to PGE
2 however, little is known
about the role of other prostanoids in the fever reaction. PGD
2
is the most abundant prostaglandin in the CNS (7). It is produced from arachidonic
acid by action of COX and PGD synthase (PGDS). Two distinct types of PGDS have
been identified, lipocalin-type PGDS (L-PGDS) and hematopoietic PGDS (H-PGDS).
L-PGDS is a secretory protein that is expressed in the brain and in male genital
organs, while H-PGDS is localized in immune and inflammatory cells (8). There
is considerable evidence that PGD
2 is involved
in the regulation of several physiological and pathophysiological processes
such as sleep induction, attraction of inflammatory cells, allergic asthma,
platelet aggregation, smooth muscle relaxation and hormone release (8, 9). An
involvement of PGD
2 in thermoregulation has
been suggested, but the data obtained so far are rather controversial, since
both hyperthermic and hypothermic effects have been observed after central administration
of PGD
2 in rats (10, 11). The purpose of this
study was to more clearly describe the role of PGD
2
in LPS-induced fever in rats. We investigated the content of PGE
2
and PGD
2 in CSF, plasma and lungs after systemic
injection of LPS. The impact of PGD
2 on the
LPS-induced fever response was further assessed by use of EDJ300520, a novel
selective inhibitor of H-PGDS.
MATERIALS AND METHODS
Animals
The ethic guidelines for investigations in conscious animals were obeyed and all procedures were approved by the local Ethics Committee for Animal Research (Regierungspräsidium Darmstadt, Germany). Fifty-seven male Sprague Dawley rats (Charles River, Sulzfeld, Germany) weighing 250-300 g were used. Animals had free access to standard rat chow and tap water and were housed in a room maintained at 22 ± 1 °C with a 12:12-h light/dark cycle (lights on 07:00 am - 07:00 pm).
Animal experiments
Studies were performed on conscious, unrestrained rats at an ambient temperature
of 22 ± 1 °C. One week before the experiment, animals were anesthetized with
an isoflurane/carbogen mix and a radiotelemetry transmitter (E-Mitter 4000 system,
Mini Mitter, Bend, OR) was inserted into the intraperitoneal cavity for continuous
recording of core body temperature (T
C) without
stress to animals. One day before the experiment, each cage was placed on a
receiver and radiotelemetry signals emitted by the implanted transmitter were
continuously monitored in intervals of 5 min using the Vitalview software (Mini
Mitter). At the day of the experiment (at 9:00 am), rats were shortly anesthetized
with isoflurane and fever was induced by intraperitoneal (
i.p.) injection
of 50 µg/kg LPS (
E. coli serotype O111:B4; Sigma Aldrich, Seelze, Germany)
dissolved at a concentration of 50 µg/ml in pyrogen-free 0.9% NaCl solution
(B. Braun, Melsungen, Germany). In experiments with the H-PGDS inhibitor EDJ300520
(Evotec, Hamburg, Germany), rats were perorally (p.o.) pretreated with EDJ300520
(10-40 mg/kg) suspended in 0.5% methyl cellulose in water, and fever was induced
1 h thereafter by
i.p. LPS injection. Three animals were investigated
per experimental day with one animal receiving either vehicle, 10 mg/kg or 40
mg/kg EDJ300520. Average T
C values for 20-min
periods were computed from T
C recorded at 5-min
intervals. For each rat, a baseline temperature was defined as the mean T
C
during the 60-min period immediately preceding fever induction. The change in
T
C (
T
C)
was calculated by subtracting the baseline temperature from each recorded T
C
value. The number of animals per group was 6-9.
For tissue harvesting, rats were deeply anesthetized with ketamine-midazolam. The neck muscles were rapidly reflected to gain access and to withdraw a cerebrospinal fluid (CSF) sample from the cisterna magna. CSF (~ 120 µl) was collected in an Eppendorf tube that was put immediately on dry ice and stored at -80 °C. Then blood was aspirated by cardiac puncture and transferred to an Eppendorf tube containing EDTA. The collected blood was immediately centrifuged (3,000 g, 3 min) and the resulting plasma was stored at -80 °C. Finally, the lungs were dissected, quickly frozen in liquid nitrogen and stored at -80 °C.
Cell culture experiments
Mouse macrophage RAW 264.7 cells (American Type Culture Collection, Wesel, Germany)
and human cervical carcinoma HeLa cells (Deutsche Sammlung für Mikroorganismen
und Zellkulturen, Braunschweig, Germany) were grown in RPMI 1640 medium with
Glutamax-1 (Invitrogen, Karlsruhe, Germany) supplemented with 10% fetal calf
serum and 1% penicillin/streptomycin and cultured at 37 °C in an atmosphere
containing 5% CO
2. RAW 264.7 cells at 4 x 10
5
cells per well and HeLa cells at 2 x 10
5 cells
per well were seeded onto 6-well plates. After 24 h, the growth medium was replaced
with fresh media and prostaglandin synthesis was stimulated by adding 100 ng/ml
LPS (
Escherichia coli 026:B6; Sigma-Aldrich, Seelze, Germany) to RAW
264.7 cells or 1 ng/ml IL-1ß and 5 ng/ml TNF
(PeproTech, London, UK) to HeLa cells. Immediately thereafter, vehicle (DMSO)
or EDJ300520 (0.1-50 µM) was added. The supernatant was collected after 16 hours
and the concentration of PGD
2 or PGE
2
was analyzed by LC-MS/MS analyses as described below.
Determination of prostaglandin concentrations
The content of PGE
2 and PGD
2
in CSF, plasma and lungs was determined by liquid chromatography-electrospray
ionization-tandem mass spectrometry (LC-MS/MS), a method that allows ultra-sensitive
detection of prostaglandins (12). As PGE
2 and
PGD
2 in vivo are rapidly inactivated
by enzymatic degradation to metabolites (for instance, the half-life in peripheral
circulation is ~ 20 sec) (13, 14)), we additionally determined the levels of
metabolites of PGE
2 and PGD
2.
The concentration of PGE
2 was then calculated
as sum of PGE
2 and the PGE
2
metabolites 15-keto PGE
2, 13,14-dihydro-15-keto-PGE
2,
13,14-dihydro-15-keto-PGA
2, bicyclo-PGE
2
and tetranor-PGEM. The concentration of PGD
2
was calculated as sum of PGD
2 and the PGD
2
metabolites 13,14-dihydro-15-keto-PGD
2, 11-ß-PGF
2alpha,
11-ß-13,14-dihydro-15-keto-PGF
2alpha,
and PGJ
2.
Sample and standard preparation: CSF samples (100 µl) were added with 100 µl
0.15 M EDTA, 80 µl 45 mM H
3PO
4
and 20 µl methanol. Plasma samples (250 µl) were added with 100 µl 0.15 M EDTA,
600 µl 45 mM H
3PO
4,
10 µl 2,6-di-tert-butyl-4-methylphenol (2 mg/ml in methanol) and 20 µl methanol.
Lung samples were cut into small pieces and homogenized thoroughly using a pellet
pestle (Kontes Glass Company, Vineland, New Jersey, USA). Homogenates (25 mg)
were suspended in 125 µl PBS. Then 100 µl 0.15 M EDTA, 80 µl 45 mM H
3PO
4
and 20 µl methanol were added. In samples for standard curves and quality control,
the CSF, plasma or lung samples were replaced by 100 µl artificial cerebrospinal
fluid, 250 µl PBS or 150 µl PBS, respectively, and the working and internal
standards were dissloved in 20 µl methanol.
Prostaglandin extraction. Extraction of prostaglandins was performed with liquid-liquid-extraction (CSF and lungs) or solid-phase-extraction (plasma). For liquid-liquid-extraction, samples were incubated twice with 600 µl ethyl acetate. The organic phase was removed at 45 °C under a gentle stream of nitrogen. The residues were reconstituted with 50 µl of acetonitrile / water / formic acid (20:80:0.0025, v/v, pH 4.0), centrifuged for 2 min at 10,000 g and transferred to glass vials (Macherey-Nagel, Düren, Germany) prior to injection into the LC-MS/MS system. For solid-phase-extraction, 1 ml Chromabond HR-X cartridges (Macherey-Nagel) were washed with 2 ml of hexane / ethyl acetate / isopropanol (35:60:5, v/v), dried for 20 sec, conditioned with 1 ml of methanol and equilibrated with 1 ml of water. One milliliter of the prepared plasma / PBS was loaded onto the column and washed with 1 ml water and 1 ml methanol / water (10:40, v/v). The cartridges were then dried for 7 min and eluted with 1 ml of hexane / ethyl acetate / isopropanol (35:60:5, v/v). Removement of the organic phase and reconsitution of residues was performed as described above.
LC-MS/MS conditions. Prostaglandins were separated with a Synergi Hydro-RP column (ID 150 x 2 mm, particle size 4 µm and pore size 80 A; phenomenex, Aschaffenburg, Germany) and determined with an API 4000 triple quadrupole mass spectrometer (Applied Biosystems, Darmstadt, Germany) as described previously (12).
Statistics
The results are expressed as means ± SEM. Statistical analysis comprised Student's t-test or analysis of variance with subsequent Bonferoni post-hoc test. P < 0.05 was considered as statistically significant.
RESULTS
Changes of PGD2 and PGE2
levels in CSF, plasma and lung during LPS-induced fever
In order to test whether PGD
2 might be involved
in the LPS-induced fever response, the content of PGD
2
and PGE
2 in CSF, plasma and lungs at various
time points after
i.p. injection of LPS were determined by LC-MS/MS analyses.
Both PGD
2 and PGE
2
were detectable in samples from saline-treated control rats (CSF: 159.7 ± 47.3
and 53.0 ± 8.0 pg/ml; plasma: 62.7 ± 10.2 and 432.4 ± 76.3 pg/ml; lung: 135.7
± 30.3 and 36.6 ± 7.1 pg/mg tissue; PGD
2 and
PGE
2, respectively). LPS injection (50 µg/kg
i.p.) evoked the typical progressive rise in T
C
during 120 to 300 min after injection, while in animals injected with saline
T
C remained stable throughout the experiment
(
Fig. 1A). The initial slight elevation of T
C
after saline or LPS injection was apparently due to the stress induced by the
injection procedure.
|
Fig. 1. Effects of LPS injection
on core body temperature (TC)
and on the content of PGE2 and PGD2
in CSF, plasma and lungs in rats. (A) Changes in TC
after i.p. injection of LPS (50 µg/kg) or saline. The injection
time point is designated time 0. Baseline TC
were 37.5 ± 0.1 °C (LPS) and 37.6 ± 0.2 °C (saline). (B-G) Levels of PGE2
and PGD2 in the CSF (B, E), plasma (C,
F) and lungs (D, G) at the indicated time points after injection of LPS
or after injection of saline (control). n = 6-9 per group * Significantly
different from control animals, P < 0.05. Data are expressed as
mean ± SEM. |
The LPS-induced changes of PGD
2 and PGE
2
levels in CSF, plasma and lungs are summarized in
Fig. 1B-G. PGE
2
was significantly increased in CSF of LPS-treated animals as compared to saline-treated
control animals at 1, 3 and 5 hours after LPS injection with maximal levels
at 3 h (
Fig. 1B). In plasma, PGE
2 was
also significantly elevated from 1 to 5 hours after LPS injection, however the
maximum PGE
2 concentration was already detected
at 1 h after LPS (
Fig. 1C). These data are consistent with recent reports
indicating that circulating PGE
2 may trigger
the early phase of LPS-induced fever, while centrally produced PGE
2
is crucial for later phases of fever (3, 15). We also investigated PGE
2
production in the lungs,
i.e. in a 'LPS-processing' organ (16). LPS injection
slightly increased the PGE
2 levels in lung tissue,
being significant at 3 h after injection (
Fig. 1D).
In contrast to PGE
2, levels of PGD
2
were not significantly altered in the CSF after LPS injection, although a tendency
towards an increase at late time points was observed (
Fig. 1E). However,
in plasma and lungs PGD
2 was elevated from 1
to 5 h (plasma) and at 3 h (lungs) after LPS injection (
Fig. 1F,G). Notably,
the time course of LPS-induced changes in PGD
2
was similar to that of PGE
2 with maximum levels
being detected at 1 h (plasma) and 3 h (lungs) after LPS. All in all, these
data confirm the pivotal role of PGE
2 in LPS-induced
fever. However, PGD
2 is also increased in plasma
and lungs following LPS injection and might therefore contribute to the fever
response by a peripheral mechanism.
Inhibition of peripheral PGD2 synthesis prevents
the LPS-induced fever
We then analyzed the effect of peripheral PGD
2
inhibition on the fever reaction by using a novel inhibitor of hematopoietic
prostaglandin D synthase (H-PGDS), EDJ300520. Selectivity of EDJ300520 towards
inhibition of PGD
2 synthesis was first investigated
in vitro. RAW 264.7 macrophages and HeLa cells were stimulated by cytokines
and the content of PGD
2 and PGE
2
in the supernatant was determined after 16 h. As shown in
Fig. 2, addition
of EDJ300520 (0.5-50µM) to the cell culture medium concentration-dependently
inhibited the cytokine-induced production of PGD
2
(
Fig. 2A), but PGE
2 levels were not altered by EDJ300520 (
Fig. 2B).
These data confirm that EDJ300520 selectively inhibits the synthesis of PGD
2
but not of PGE
2 in vitro.
|
Fig. 2. EDJ300520 inhibits
PGD2 synthesis in vitro. RAW 264.7
cells were stimulated with 100 ng/ml LPS (A), and HeLa cells were stimulated
with 1 ng/ml IL-1ß and 5 ng/ml TNF-
(B). Immediately thereafter, vehicle (DMSO) or EDJ300520 at the indicated
concentrations was added. The supernatant was collected after 16 hours
and the concentration of PGD2 (A) or
PGE2 (B) was determined. Data are expressed
as mean ± SEM and show the results of four (A) or three (B) independent
experiments. * Significantly different from LPS-treated vehicle group,
P < 0.05. |
In order to inhibit H-PGDS, we applied EDJ300520 orally to rats 1 h prior to
i.p. LPS injection and analyzed the changes in T
C
as well as the content of PGD
2 and PGE
2
in CSF, plasma and lungs. Administration of EDJ300520 without any other stimulus
did not change T
C as compared to vehicle treatment
(data not shown). However, when EDJ300520 was administered 1 h before
i.p.
LPS, an unexpected hypothermic response to LPS occurred during the first 3 h
with a maximal drop in T
C of ~ 0.7 °C at 100
min after LPS (
Fig. 3A). Thereafter, T
C
returned to baseline, but the typical LPS-induced febrile T
C
rise did not occur (
Fig. 3A). The contents of PGD
2
and PGE
2 were determined at the end of the observation
period,
i.e. 5 h after LPS injection. PGE
2
levels in CSF, plasma and lungs were not affected by treatment with EDJ300520
(
Fig. 3B-D). CSF levels of PGD
2 were
also not significantly altered after administration of the H-PGDS inhibitor
(
Fig. 3 E). However, the content of PGD
2
in plasma and lungs was significantly reduced as compared to vehicle-treated
animals (
Fig. 3 F,G). These data show that (i) EDJ300520
in vivo
selectively blocks the LPS-induced peripheral PGD
2
synthesis, and that (ii) H-PGDS mediated PGD
2
synthesis is required for a febrile response to
i.p. LPS.
|
Fig. 3. EDJ300520 inhibits
peripheral PGD2 synthesis and prevents
the LPS-induced fever in rats. (A) Changes in core body temperature (TC)
after p.o. administration of 10 mg/kg EDJ300520, 40 mg/kg EDJ300520 or
vehicle, followed by i.p. injection of 50 µg/kg LPS 1 h thereafter.
The LPS injection time point is designated time 0. Baseline TC
were 37.4 ± 0.1 °C (10 mg/kg EDJ300520), 37.6 ± 0.2 °C (40 mg/kg EDJ300520),
and 37.6 ± 0.2 °C (vehicle). n = 6 per group. *, † Significantly
different from vehicle group (P < 0.05) for 10 and 40 mg/kg EDJ300520,
respectively. (B-G) Levels of PGE2 and
PGD2 in the CSF (B, E), plasma (C, F)
and lungs (D, G) 5 h after LPS injection. * Significantly different from
vehicle group, P < 0.05. Data are expressed as mean ± SEM. |
DISCUSSION
PGE
2 has long been known as the principal mediator
of the febrile response. In contrast, the role of PGD
2
in LPS-induced fever is poorly understood. We here demonstrate that systemic
LPS injection increases the production not only of PGE
2
but also that of PGD
2 in the periphery,
i.e.
in plasma and lungs. Interestingly, inhibition of LPS-induced, peripheral PGD
2
production by a selective H-PGDS inhibitor prevents the fever reaction in response
to LPS injection. Therefore, peripherally generated PGD
2
seems to be implicated in the mechanisms underlying fever.
There is considerable evidence that the entire febrile course needs
de novo
synthesis of PGE
2 and that the PGE
2-synthesizing
enzymes are induced in the brain and in peripheral organs. As a result, increased
levels of PGE
2 in both CSF and plasma have been
detected after injection of LPS and other pyrogens (14, 16-21). Recent data
indicate that LPS-induced PGE
2 synthesis is
more rapidly activated in peripheral tissues than in the brain. The peripherally
generated, circulating PGE
2 is thought to cross
the blood-brain barrier and to cause the early phase of fever which occurs in
a thermoneutral environment after
i.v. LPS injection (3, 22). The LPS-induced
changes of PGE
2 content in CSF and plasma described
in the present study agree well with this hypothesis, since the highest PGE
2
levels were detected in plasma already 1 h after LPS injection, while the PGE
2
levels in CSF peaked after 3 h. About the source of the rapid PGE
2
increase in plasma one can only speculate. In the lungs, the PGE
2
content was significantly increased only at 3 h after LPS and it is therefore
unlikely that the lungs are the locus of rapid, LPS-induced PGE
2
production. Other LPS-processing organs such as the liver might be involved,
but this was not investigated in the present study.
Our data further demonstrate that, similar to PGE
2,
the synthesis of PGD
2 is also increased in plasma
and lungs in response to systemic LPS injection. However, in contrast to PGE
2,
the LPS injection did not affect the levels of PGD
2
in the CSF. We concluded that peripherally generated PGD
2
might modulate the febrile response and therefore we investigated the effects
of an inhibitor of H-PGDS, which mainly mediates the synthesis of PGD
2
in peripheral organs (8, 23). Most notably, oral pretreatment with the H-PGDS
inhibitor EDJ300520 (i) prevented the LPS-induced PGD
2
increase in plasma and lungs, (ii) prevented the LPS-induced fever response,
and (iii) induced a hypothermia that started ~ 60 min and peaked ~ 100 min after
LPS injection. The mechanisms of a hypothermic response to bacterial endotoxin
are poorly understood. In general, LPS injection can evoke either fever or hypothermia
in rats. Two critical factors that influence the outcome are the LPS dose and
the thermal environment (24, 25). However, in our experiments all rats received
the same dose of LPS and the ambient temperature was also the same. Thus, peripherally
generated PGD
2 is obviously an additional critical
factor that decides whether systemic LPS injection induces fever or hypothermia.
In summary, our experiments demonstrate that peripherally produced PGD
2
is involved in the mechanisms underlying fever. Additional studies are needed
to explore the exact mechanism by which PGD
2
modulates the fever response.
Acknowledgements:
Our studies were supported in part by Evotec, Hamburg, Germany, by the Deutsche
Forschungsgemeinschaft DFG GE695 and by the LOEWE Lipid Signaling Forschungszentrum
Frankfurt (LiFF). Evotec did not influence the design, performance or results
of the study. We thank Inga Rauhmeier for excellent technical assistance.
Conflict of interests: None declared.
REFERENCES
- Engblom D, Saha S, Engstrom L et al. Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis. Nat Neurosci 2003; 6(11): 1137-1138.
- Schiltz JC, Sawchenko PE. Distinct brain vascular cell types manifest inducible cyclooxygenase expression as a function of the strength and nature of immune insults. J Neurosci 2002; 22(13): 5606-5618.
- Steiner AA, Ivanov AI, Serrats J et al. Cellular and molecular bases of the initiation of fever. PLoS Biol 2006; 4(9): E284.
- Ushikubi F, Segi E, Sugimoto Y et al. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 1998; 395(6699): 281-284.
- Oka T, Oka K, Saper CB. Contrasting effects of E type prostaglandin (EP) receptor agonists on core body temperature in rats. Brain Res 2003; 968(2): 256-262.
- Ivanov AI, Romanovsky AA. Prostaglandin E2
as a mediator of fever: synthesis and catabolism. Front Biosci 2004; 9:
1977-1993.
- Narumiya S, Ogorochi T, Nakao K, Hayaishi O. Prostaglandin D2 in rat brain, spinal cord and pituitary: basal level and regional distribution. Life Sci 1982; 31(19): 2093-2103.
- Kanaoka Y, Urade Y. Hematopoietic prostaglandin D synthase. Prostaglandins Leukot Essent Fatty Acids 2003; 69(2-3): 163-167.
- Urade Y, Hayaishi O. Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim Biophys Acta 2000; 1482(1-2): 259-271.
- Sri Kantha S, Matsumura H, Kubo E et al. Effects of prostaglandin D2, lipoxins and leukotrienes on sleep and brain temperature of rats. Prostaglandins Leukot Essent Fatty Acids 1994; 51(2): 87-93.
- Ueno R, Narumiya S, Ogorochi T, Nakayama T, Ishikawa Y, Hayaishi O. Role of prostaglandin D2 in the hypothermia of rats caused by bacterial lipopolysaccharide. Proc Natl Acad Sci USA 1982; 79(19): 6093-6097.
- Schmidt R, Coste O, Geisslinger G. LC-MS/MS-analysis of prostaglandin E2 and D2 in microdialysis samples of rats. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 826(1-2): 188-197.
- Eguchi N, Kaneko T, Urade Y, Hayashi H, Hayaishi O. Permeability of brain structures and other peripheral tissues to prostaglandins D2, E2 and F2 alpha in rats. J Pharmacol Exp Ther 1992; 262(3): 1110-1120.
- Davidson J, Abul HT, Milton AS, Rotondo D. Cytokines and cytokine inducers stimulate prostaglandin E2 entry into the brain. Pflugers Arch 2001; 442(4): 526-533.
- Perlik V, Li Z, Goorha S, Ballou LR, Blatteis CM. LPS-activated complement, not LPS per se, triggers the early release of PGE2 by Kupffer cells. Am J Physiol Regul Integr Comp Physiol 2005; 289(2): R332-R339.
- Ivanov AI, Pero RS, Scheck AC, Romanovsky AA. Prostaglandin E2-synthesizing enzymes in fever: differential transcriptional regulation. Am J Physiol Regul Integr Comp Physiol 2002; 283(5): R1104-R1117.
- Rotondo D, Abul HT, Milton AS, Davidson J. Pyrogenic immunomodulators increase the level of prostaglandin E2 in the blood simultaneously with the onset of fever. Eur J Pharmacol 1988; 154(2): 145-152.
- Ivanov AI, Scheck AC, Romanovsky AA. Expression of genes controlling transport and catabolism of prostaglandin E2 in lipopolysaccharide fever. Am J Physiol Regul Integr Comp Physiol 2003; 284(3): R698-R706.
- Tavares E, Minano FJ, Maldonado R, Dascombe MJ. Endotoxin fever in granulocytopenic rats: evidence that brain cyclooxygenase-2 is more important than circulating prostaglandin E2. J Leukoc Biol 2006; 80(6): 1375-1387.
- Walentynowicz K, Szefer M, Wojtal B, Terlecki P, Wrotek S, Kozak W. Role of prostaglandins in heme-induced fever. J Physiol Pharmacol 2006; 57 (Suppl 8): 73-82.
- Soszynski D, Chelminiak M. Intracerebroventricular injection of neuronal and inducible nitric oxide synthase inhibitors attenuates fever due to LPS in rats. J Physiol Pharmacol 2007; 58(3): 551-561.
- Ootsuka Y, Blessing WW, Steiner AA, Romanovsky AA. Fever response to intravenous prostaglandin E2 is mediated by the brain but does not require afferent vagal signaling. Am J Physiol Regul Integr Comp Physiol 2008; 294(4): R1294-R1303.
- Urade Y, Hayaishi O. Prostaglandin D synthase: structure and function. Vitam Horm 2000; 58: 89-120.
- Romanovsky AA, Kulchitsky VA, Simons CT, Sugimoto N. Methodology of fever research: why are polyphasic fevers often thought to be biphasic? Am J Physiol 1998; 275(1 Pt 2): R332-R338.
- Steiner AA, Dogan MD, Ivanov AI et al. A new function of the leptin receptor: mediation of the recovery from lipopolysaccharide-induced hypothermia. FASEB J 2004; 18(15): 1949-1951.